Hepatitis D Virus Infection Competitive Assessment Report 2020: Emerging Therapies and Key Pharma Players involved

 Breaking News
  • No posts were found

Hepatitis D Virus Infection Competitive Assessment Report 2020: Emerging Therapies and Key Pharma Players involved

February 17
19:40 2021
Hepatitis D Virus Infection Competitive Assessment Report 2020: Emerging Therapies and Key Pharma Players involved

DelveInsight Business Research LLP
Hepatitis D Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hepatitis D market. A detailed picture of the Hepatitis D pipeline landscape is provided, which includes the disease overview and Hepatitis D treatment guidelines.
DelveInsight launched a new report on Hepatitis D Virus Infection Pipeline Insights 2020.
 
Hepatitis D Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hepatitis D market. A detailed picture of the Hepatitis D pipeline landscape is provided, which includes the disease overview and Hepatitis D treatment guidelines. 
 
 
HDV is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV requires hepatitis B virus (HBV) for its replication. HDV infection occurs as co-infection or as super-infection with HBV.
 
Request for a detailed sample copy of the report @https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight
 
 
In the 7MM, the Total Diagnosed Prevalent cases of HDV were 204,976 cases in 2017.
 
These cases are expected to grow with a significant CAGR in the study period 2017–2030.

Emerging Therapies:

1. Hepcludex/Bulevirtide

2. Lonafarnib

3. JNJ-3989

Key pharma players involved:

1. Hepcludex/Bulevirtide

2. Eiger Biopharmaceuticals

3. Janssen Pharmaceuticals

Click here and download free sample pages of the report.

Table of contents:

1. Report Introduction

2. Hepatitis D 

3. Hepatitis D Current Treatment Patterns

4. Hepatitis D – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Hepatitis D Late Stage Products (Phase-III)

7. Hepatitis D Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hepatitis D Discontinued Products

13. Hepatitis D Product Profiles

14. Hepatitis D Key Companies

15. Hepatitis D Key Products

16. Dormant and Discontinued Products

17. Hepatitis D Unmet Needs

18. Hepatitis D Future Perspectives

19. Hepatitis D Analyst Review  

20. Appendix

21. Report Methodology

Download our full report: https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories